Covey DP et al. |
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease. |
2018 |
Neuropsychopharmacology |
pmid:29925886
|
Sarchielli P et al. |
Endocannabinoids in chronic migraine: CSF findings suggest a system failure. |
2007 |
Neuropsychopharmacology |
pmid:17119542
|
Maccarrone M et al. |
Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. |
2010 |
Neuropsychopharmacology |
pmid:20393458
|
Shimizu T et al. |
Possible inhibitory role of endogenous 2-arachidonoylglycerol as an endocannabinoid in (±)-epibatidine-induced activation of central adrenomedullary outflow in the rat. |
2015 |
Neuropharmacology |
pmid:25882827
|
Eroli F et al. |
Differential neuromodulatory role of endocannabinoids in the rodent trigeminal sensory ganglion and cerebral cortex relevant to pain processing. |
2018 |
Neuropharmacology |
pmid:29225040
|
Walentiny DM et al. |
Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. |
2015 |
Neuropharmacology |
pmid:25698527
|
Kortleven C et al. |
Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. |
2012 |
Neuropharmacology |
pmid:22884466
|
Nader J et al. |
Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. |
2014 |
Neuropharmacology |
pmid:24709540
|
Pasquarelli N et al. |
Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. |
2015 |
Neuropharmacology |
pmid:25497453
|
Moreira FA et al. |
Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. |
2008 |
Neuropharmacology |
pmid:17709120
|
Chiu CQ and Castillo PE |
Input-specific plasticity at excitatory synapses mediated by endocannabinoids in the dentate gyrus. |
2008 |
Neuropharmacology |
pmid:17706254
|
Vellani V et al. |
Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. |
2008 |
Neuropharmacology |
pmid:18329052
|
Citraro R et al. |
Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. |
2013 |
Neuropharmacology |
pmid:23206503
|
Al-Hayani A et al. |
The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. |
2001 |
Neuropharmacology |
pmid:11747904
|
Darmani NA et al. |
Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. |
2005 |
Neuropharmacology |
pmid:15921709
|
Desroches J et al. |
Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CBâ‚ and CBâ‚‚ receptors. |
2014 |
Neuropharmacology |
pmid:24148808
|
Morgan NH et al. |
Functional CB2 type cannabinoid receptors at CNS synapses. |
2009 |
Neuropharmacology |
pmid:19616018
|
Wilkerson JL et al. |
The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. |
2017 |
Neuropharmacology |
pmid:27890602
|
Piomelli D |
The endogenous cannabinoid system and the treatment of marijuana dependence. |
2004 |
Neuropharmacology |
pmid:15464150
|
Sticht MA et al. |
Endocannabinoid regulation of nausea is mediated by 2-arachidonoylglycerol (2-AG) in the rat visceral insular cortex. |
2016 |
Neuropharmacology |
pmid:26541329
|